CU20230009A7 - Composiciones farmacéuticas que comprenden compuestos derivados de (r)-n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6- il)-2-(2-metilpiridin-4-il) oxazol-4 -carboxamida, útiles como inhibidores de irak - Google Patents
Composiciones farmacéuticas que comprenden compuestos derivados de (r)-n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6- il)-2-(2-metilpiridin-4-il) oxazol-4 -carboxamida, útiles como inhibidores de irakInfo
- Publication number
- CU20230009A7 CU20230009A7 CU2023000009A CU20230009A CU20230009A7 CU 20230009 A7 CU20230009 A7 CU 20230009A7 CU 2023000009 A CU2023000009 A CU 2023000009A CU 20230009 A CU20230009 A CU 20230009A CU 20230009 A7 CU20230009 A7 CU 20230009A7
- Authority
- CU
- Cuba
- Prior art keywords
- morpholinooxazolo
- iraq
- methylpyridin
- oxazole
- carboxamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- VAELWSLNTRVXQS-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC=N1 VAELWSLNTRVXQS-UHFFFAOYSA-N 0.000 title 1
- SJHNWSAWWOAWJH-MRXNPFEDSA-N N-[5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide Chemical compound O[C@H]1CN(CC1)C1=C(C=C2C(=N1)N=C(O2)N2CCOCC2)NC(=O)C=2N=C(OC2)C2=CC(=NC=C2)C SJHNWSAWWOAWJH-MRXNPFEDSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060413P | 2020-08-03 | 2020-08-03 | |
| US202063115312P | 2020-11-18 | 2020-11-18 | |
| PCT/US2021/030192 WO2022031330A1 (en) | 2020-08-03 | 2021-04-30 | Compositions and methods for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20230009A7 true CU20230009A7 (es) | 2023-09-07 |
Family
ID=80117618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2023000009A CU20230009A7 (es) | 2020-08-03 | 2021-04-30 | Composiciones farmacéuticas que comprenden compuestos derivados de (r)-n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6- il)-2-(2-metilpiridin-4-il) oxazol-4 -carboxamida, útiles como inhibidores de irak |
Country Status (12)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311677B2 (en) | 2014-01-13 | 2025-06-01 | Aurigene Oncology Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| CA3214747A1 (en) | 2021-04-08 | 2022-10-13 | Reinhard Von Roemeling | Combination therapies for the treatment of cancer |
| WO2023172640A1 (en) * | 2022-03-08 | 2023-09-14 | X4 Pharmaceuticals, Inc. | Treatments for single-mutant waldenström's macroglobulinemia |
| CA3251930A1 (en) * | 2022-05-11 | 2023-11-16 | Curis, Inc. | TREATMENT OF DISEASES AND DISORDERS WITH MIRACLES MODIFYING COMPOUNDS 4 |
| WO2024027750A1 (en) * | 2022-08-02 | 2024-02-08 | Beigene Switzerland Gmbh | Methods of treating pulmonary hypertension using btk inhibitors |
| WO2025208000A1 (en) * | 2024-03-29 | 2025-10-02 | Curis, Inc. | Methods of treating cancer in patients with altered protein expression |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311677B2 (en) * | 2014-01-13 | 2025-06-01 | Aurigene Oncology Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| WO2016174183A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| US20170035881A1 (en) * | 2015-10-19 | 2017-02-09 | Acerta Pharma B.V. | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor |
| CN120267671A (zh) * | 2017-03-31 | 2025-07-08 | 奥锐金肿瘤有限公司 | 用于治疗血液病的化合物和组合物 |
| EP4410377A3 (en) * | 2017-10-31 | 2024-11-13 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
| EP3800188A1 (en) * | 2019-10-02 | 2021-04-07 | Bayer AG | Substituted pyrazolopyrimidines as irak4 inhibitors |
| CA3199157A1 (en) * | 2020-11-18 | 2022-05-27 | Reinhard Von Roemeling | Methods of treating diseases and disorders |
| CA3214747A1 (en) * | 2021-04-08 | 2022-10-13 | Reinhard Von Roemeling | Combination therapies for the treatment of cancer |
-
2021
- 2021-04-30 AU AU2021321350A patent/AU2021321350A1/en active Pending
- 2021-04-30 MX MX2023001296A patent/MX2023001296A/es unknown
- 2021-04-30 BR BR112023001861A patent/BR112023001861A2/pt unknown
- 2021-04-30 KR KR1020237007466A patent/KR20230048358A/ko active Pending
- 2021-04-30 IL IL300310A patent/IL300310A/en unknown
- 2021-04-30 EP EP21852519.4A patent/EP4188368A4/en active Pending
- 2021-04-30 CU CU2023000009A patent/CU20230009A7/es unknown
- 2021-04-30 CN CN202180057734.1A patent/CN116419752A/zh active Pending
- 2021-04-30 CA CA3188171A patent/CA3188171A1/en active Pending
- 2021-04-30 US US18/019,400 patent/US20230310444A1/en active Pending
- 2021-04-30 WO PCT/US2021/030192 patent/WO2022031330A1/en not_active Ceased
- 2021-04-30 JP JP2023507267A patent/JP2023537477A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188368A1 (en) | 2023-06-07 |
| MX2023001296A (es) | 2023-02-22 |
| US20230310444A1 (en) | 2023-10-05 |
| AU2021321350A1 (en) | 2023-03-16 |
| JP2023537477A (ja) | 2023-09-01 |
| BR112023001861A2 (pt) | 2023-03-07 |
| WO2022031330A1 (en) | 2022-02-10 |
| EP4188368A4 (en) | 2024-09-04 |
| KR20230048358A (ko) | 2023-04-11 |
| CN116419752A (zh) | 2023-07-11 |
| CA3188171A1 (en) | 2022-02-10 |
| IL300310A (en) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20210009A7 (es) | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) | |
| EA201990904A1 (ru) | 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| ECSP22026478A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| MY209034A (en) | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors | |
| BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| BRPI1009333B8 (pt) | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica | |
| BR112022006202A2 (pt) | Compostos heterocíclicos de arila como bloqueadores de canal do agitador de potássio kv1,3 | |
| JO2962B1 (en) | Aminopronic derivatives substituted as niprilicin inhibitors | |
| BR112013006936A2 (pt) | composto de amida substituída | |
| BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
| BR112016007427A2 (pt) | compostos de pirazol-amida e usos dos mesmos | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| TR201904158T4 (tr) | Osteoartrit tedavisi için adamts inhibitörleri olarak 5-[(piperazin-1-il)-3-okso-propil]-imidazolidin-2,4-dion türevleri. | |
| BRPI0809542A8 (pt) | Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos | |
| PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
| BR112022006292A2 (pt) | Compostos heterobicílicos de arila como bloqueadores de canais de agitador de potássio kv1.3 | |
| MX2022013890A (es) | Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos. | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| MX2023015490A (es) | Inhibidores de las transglutaminasas. | |
| BR112022006250A2 (pt) | Compostos heterobicíclicos de arila como bloqueadores de canal de agitador de potássio kv1.3 | |
| CL2023003921A1 (es) | Inhibidores de transglutaminasas | |
| MX2024011755A (es) | Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2) | |
| BR112023014549A2 (pt) | Compostos derivados substituídos com ip4-4,6 |